期刊文献+

右丙亚胺对表阿霉素所致心脏毒性保护作用的临床观察

暂未订购
导出
摘要 目的:观察右丙亚胺(dexrazoxane,DEX)对乳腺癌患者术后表阿霉素(EPI)联合化疗时的心脏保护作用及可能作用机制。方法:50例乳腺癌患者,随机分为观察组和对照组,每组25例,2组患者均采用EPI为主的联合化疗方案,观察组化疗基础上加用DEX(DEX∶EPI=10∶1),在第1次应用EPI时即给予DEX。2组患者均按要求完成4个化疗周期,所有患者连续随访1年,采用心肌钙蛋白T(cTnt)、心电图和左心室射血分数(LVEF)监测治疗前、治疗后每周期、治疗后半年、治疗后1年的心脏功能状态,同时观察治疗的非心脏毒性。结果:2组心电图异常变化从4周期开始,治疗半年和1年,2组心电图异常差异均有统计学意义(P<0.05~P<0.01),2组cTnt和LVEF从1周期后相比,差异均有统计学意义(P<0.01)。2组的非心脏毒性差异均无统计学意义(P>0.05)。结论:EPI从第1次应用时就对心脏产生毒性,DEX可以起到明显保护心脏作用,不良反应可以耐受,有临床应用价值。
出处 《蚌埠医学院学报》 CAS 2012年第9期1100-1102,共3页 Journal of Bengbu Medical College
  • 相关文献

参考文献10

  • 1Lipsbultz SE,Rifai N,Dalton VM,et a/. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia [ J ]. N Ensl J Med ,2004,351 (2) : 145 - 153.
  • 2Ramirez-Ramirez MA, Sobrino-Cossio S, de la Mora-Levy JG, et al. Loss of expression of DNA mismatch repair proteins in aberrant crypt foci identified in vivo by magnifying colonoscopy in subjects with hereditary nonpolyposic and sporadic colon rectal cancer[ J]. J Gastrointest Cancer,2012,12 (2) :209 - 214.
  • 3Swain SM, Viei P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review [ J]. J Cancer Res Clin Oncol,2004,130( 1 ) :1 -7.
  • 4Venturini M,Miehelotti A,Del Mastro L,et al controlled clinical trial to evaluate eadioprotection in women receiving epirubicin chemotherapy for advanced breast cancer [ J ]. J Clin 0nco1,1996,14(5) :3112 -3120.
  • 5Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia : results of Dana-Farber Consortium Protocol 91 - 01 [ J ]. Blood, 2001,97 ( 5 ) : 1211 - 1218.
  • 6Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for eardio-oncology and cardiooncological prevention[J]. J Nail Cancer Inst,2010,102( 1 ) :14 -25.
  • 7Marry M, Espi6 M, Llombart A, et al. Multicenter randomized phase m study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracyeline-based ehemotherapy [ J ]. Ann Oneol, 2006,17(4) :614 -622.
  • 8Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukacmia:long-term follow-up of a prospective, randomised, muhicentre trial [ J ]. Lancet Oncol, 2010,11 (10) :950 - 961.
  • 9Herman EH, Lipshultz SE, Ferrans VJ. The use of cardiac biomarkers to detect myocardial damage induced bychemotherapeutic agents [ M]//Wu AHB. Cardiac markers. 2nd ed. NJ : Humana Press ,2003:87 - 109.
  • 10庄海峰,张宇,蔡皎皓,沈建平.右丙亚胺联合参麦注射液降低蒽环类药物心脏毒性的临床研究[J].中国肿瘤临床,2012,29(6):348-351. 被引量:19

二级参考文献8

  • 1Elliott P.Pathogenesis of cardiotoxicity induced by anthracyclines[J].Semin Oncol,2006,33(3 Suppl 8):S2-S7.
  • 2Cvetkovi RS,ScottLJ.Dexrazoxane:a review of its use for cardiop rotection during anthracycline chemotherapy[J].Drugs,2005,65 (7):1005-1024.
  • 3Thomas L,Bellmont S,Christen MO,et al.Cardiovascular and sur-vival effects of sympatho-inhibitors in adriamycin-induced cardio-myopathy in rats[J].Fundam Clin Pharmacol,2004,18(6):649-655.
  • 4Koukourakis MI.Am ifostine in clinical oncology:current use and future Applications[J].Anticancer Drugs,2002,13(3):z181-z209.
  • 5Stolarska M,Mlynarski W,Zalewska-Szewczyk B,et al.Cytopro-tective effect of am ifostine in the treatment of childhood neoplastic diseases-a clinical study including the pharmacoeconomic analysis[J].Pharmacol Rep,2006,58(1):30-34.
  • 6邵维维,邵宗鸿.蒽环类药物的心脏毒性及防治进展[J].中国实用内科杂志,2008,28(9):779-781. 被引量:34
  • 7车菲菲,刘瑜,徐才刚.右丙亚胺对阿霉素引起的心脏毒性防治效果及其机制研究[J].四川大学学报(医学版),2010,41(1):24-28. 被引量:35
  • 8高承贤,丁志山,程东庆,袁巍,方三华.参麦注射液对老年大鼠心肌缺血再灌注心肌细胞凋亡干预作用[J].中医药学刊,2003,21(3):360-360. 被引量:23

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部